and Rü diger von Kries 5 BACKGROUND: We investigated whether obese pregnant women negative for gestational diabetes (GDM) still experience dysglycemia, as indicated by high glycated hemoglobin (Hb A 1c ) at delivery, and whether this impacts offspring and long-term maternal outcomes.
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Adequate procedures for diagnosis of gestational diabetes (GDM) 7 have been a subject of controversy (1 ) . Recently, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) recommended the use of a single increased value applying newly defined glucose cutoffs for fasting glucose or 1 or 2 h after a 75-g glucose load [oral glucose tolerance test (OGTT)] (2 ), rather than 2 increased values as recommended by the American College of Obstetricians and Gynecologists (3 ). This decision was based on the finding of continuous relationships between maternal glucose concentrations and adverse pregnancy outcomes including macrosomia, as demonstrated by the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study (4 ) . In addition to the international controversy regarding the optimal screening and diagnostic strategy, there is no consensus on specific recommendations for obese pregnant women, who are at high risk for glycometabolic disturbances (3, 5, 6 ) .
A substantially higher proportion of obese than normal-weight women develop metabolic abnormalities, including glucose intolerance, during pregnancy, which is associated with increased later-life health risks in both mothers and offspring (7 ) . Despite OGTT values within the reference range during pregnancy, children of mothers with preconception obesity had an increased prevalence of overweight (8 ) . Although this might be the result of genetic background and lifestyle factors related to maternal obesity, it could also reflect effects on offspring outcome of a metabolically altered intrauterine milieu characterized by lipotoxicity owing to lipid accumulation in nonadipose tissues (9 ) and hyperglycemia even below diagnostic cutoffs for GDM. Excess placental lipid accumulation has been shown to activate signaling cascades including proinflammatory cytokines and oxidative stress (9 ) , with potential effects on fetal growth and liver metabolism, as suggested from animal models (10, 11 ) .
We recently found high concentrations of glycated hemoglobin (Hb A 1c ) in obese women at delivery, although GDM had been previously excluded according to the stringent IADPSG criteria (12 ) . To assess the relevance in obese GDM-negative women, we defined a cutoff value for maternal Hb A 1c at delivery and investigated the influence of high Hb A 1c on offspring outcomes, including large-for-gestational-age (LGA) birth weights and cord-blood serum C-peptide concentrations. We further assessed effects on long-term postpartum measures of mothers' glucose metabolism and inflammation at Ͼ2 years after delivery. Data of 462 mother-child pairs of our prospective Programming of Enhanced Adiposity Risk in Childhood -Early Screening (PEACHES) cohort study were analyzed.
Materials and Methods

STUDY DESIGN AND PARTICIPANTS
The prospective mother-child cohort study PEACHES investigates the long-term effects of preconception maternal obesity on the development of overweight and associated metabolic diseases in mothers and their offspring. Initiated in 2010, this ongoing study recruits obese pregnant women during their first contact at the maternity clinic of one of 23 obstetrics and gynecology departments in Bavaria, southern Germany, and parts of northern Germany (4 -6 weeks before the due date). Inclusion criteria are age Ն18 years, singleton pregnancy, gestational age at birth of Ն37 weeks, and pregestational body mass index (BMI) Ն30 kg/m 2 . Women with a preexisting diagnosis of type 1 or type 2 diabetes or other chronic diseases before pregnancy and giving birth to offspring with malformations and/or genetic defects are excluded. As a control group, healthy and GDMnegative normal-weight women with preconception BMI 18.5-24.9 kg/m 2 were recruited in these hospitals. The study was approved by the local ethics committee of the Ludwig-Maximilians-Universität München, Germany (protocol no. 165-10). Written informed consent was obtained from participants.
Between August 2010 and August 2014, we consecutively enrolled 885 obese and normal-weight women who had OGTTs according to stringent criteria (2 ) (Fig.  1 ). Data were analyzed from 462 GDM-negative white women and their children. GDM was excluded when none of the 3 glucose concentrations of a 75-g OGTT met or exceeded the reference values according to the IADPSG criteria (1-step method, n ϭ 299):
In the 2-step approach (n ϭ 163), a positive 50-g glucose challenge test (GCT), defined as 1-h glucose concentration Ն140 mg/dL (Ն7.8 mmol/L) (13) (14) (15) [positive GCT, n ϭ 13, median 149 mg/dL (8.3 mmol/L); negative GCT, n ϭ 150, median 112 mg/dL (6.2 mmol/L)], was followed by a 75-g 2-h OGTT according to IADPSG diagnostic criteria. Screening or testing occurred between 23 weeks and 1 day and 32 weeks and 6 days of gestation (4 ) (median 25 weeks and 4 days). We included women with a negative 50-g GCT or 75-g OGTT performed before 23 weeks and 1 day if absence of GDM was confirmed later in pregnancy.
DATA COLLECTION AND SAMPLE ANALYSES
Prenatal care, delivery, and neonatal parameters. We obtained information on maternal pregravid BMI and gestational weight gain (GWG) from the "maternity pass" issued to every pregnant woman at her first antenatal visit to the gynecologist. Maternal pregravid BMI was based on data measured at this first visit if the visit was before gestational week 12 (87% of cases), or on the woman's BMI before pregnancy as requested at the first antenatal visit and documented in the maternity pass if the visit was later. As recommended by 2009 Institute of Medicine guidelines, we classified GWG (difference between the last measured weight before delivery and preconception weight) as inadequate, adequate, or excessive depending on the preconception BMI (16 ) . We obtained data on OGTT from the maternity pass or, in case of missing values, the mothers' gynecologists. Data on smoking during pregnancy were obtained twice, via a questionnaire sent to each participant and a telephone interview shortly after delivery. Reported smoking at either assessment was categorized as maternal smoking at "any time during pregnancy" or "no time during pregnancy." Data on breastfeeding obtained from the questionnaire were di-chotomized as "Ն1 month exclusively without interruption" or "never or Ͻ1 month exclusively." Offspring sex, birth weight, and gestational age were abstracted from birth records. Information on the occurrence of hypoglycemia and neonatal care admissions including duration, reason for admission, symptoms, and treatment was provided via the questionnaire and/or phone interview.
Maternal EDTA-containing plasma samples obtained at delivery were transported promptly to a central laboratory for analysis of Hb A 1c by HPLC via cationexchange chromatography with a Tosoh G8 HPLC Analyzer (Tosoh Bioscience) [interassay CV Յ2.0%, analytic bias Յ0.03% Hb A 1c at a target value of 5.44% (36.0 mmol/mol)]. A complete blood count was performed in mothers at delivery to exclude iron deficiency anemia as a potential cause of increased Hb A 1c (17 ) .
Umbilical cord blood was collected, centrifuged (2500g, 22°C), and sent to the central laboratory for analysis of serum C-peptide concentrations with a chemiluminescence immunoassay (Abbott Architect i2000).
Maternal postpartum follow-up visit. Women were consecutively invited to a maternal follow-up visit several years postpartum for evaluation of metabolic health and body composition, if inclusion criteria were fulfilled: time interval Ͼ2 years postpartum, no subsequent pregnancy, and willingness to participate. Data of 42 obese women who had negative GDM testing and were followed until March 2015 were available for analysis ( Fig.  1) . At delivery, 20 of them had Hb A 1c Ն5.7% (39 mmol/mol), and 22 had Hb A 1c Ͻ5.7% (39 mmol/mol). In addition, we analyzed the postpartum data of 19 obese A subgroup of obese GDM-negative women was followed at 2.9 years (median) postpartum.
High Hb A 1c at Delivery in Obese Nondiabetic Women white women who tested positive for GDM according to the IADPSG criteria (1-step method) and fulfilled criteria for follow-up. Anthropometric and laboratory methods are outlined in the online Supplemental Data, which accompanies the online version of this article at http://www.clinchem.org/content/vol61/issue11.
EXPOSURE AND OUTCOME VARIABLES
The main explanatory variable was increased maternal Hb A 1c Ն5.7% (39 mmol/mol) at delivery despite prior exclusion of GDM. Outcome parameters in offspring were LGA status (defined as birth weight Ͼ90th percentile (18 )), birth weight, and cord-blood serum C-peptide concentrations, as well as neonatal hypoglycemia, severe hypoglycemia (defined by the presence of symptoms and/or treatment with intravenous glucose), and neonatal care admissions. Maternal postpartum outcomes referred to systemic biomarkers of dysglycemia and inflammation including Hb A 1c , fasting glucose, highsensitivity C-reactive protein (hsCRP), and fibrinogen concentrations.
STATISTICAL ANALYSIS
To compare the characteristics of normal-weight and obese GDM-negative women as well as subgroups of obese GDM-negative women, we used t-tests for numerical data and 2 tests for categorical data. A cumulative distribution curve of maternal Hb A 1c at delivery for normal-weight GDM-negative women was drawn to locate the 90th percentile in the distribution. For offspring comparisons, when maternal Hb A 1c at delivery was above or below the boundary limit, univariate and multiple logistic regression models were calculated for binary dependent variables, and univariate and multiple linear regression models were calculated for metric dependent variables.
We assessed the relationship of maternal Hb A 1c at delivery with mothers' later metabolic and inflammatory status, including Hb A 1c concentrations several years postpartum. For sample size calculations, we applied an increment of 0.5% (5.5 mmol/mol) in postpartum Hb A 1c , which had previously been considered clinically relevant (19 ) . On the basis of the reported variance of a general female population (20 ) , we identified a sample size of 15 mothers with an Hb A 1c at delivery Ն5.7% and Ͻ5.7% (39 mmol/mol) to be sufficient to detect such a difference with a type I error probability (␣) of 0.05 and a power of 0.9. Univariate and multiple linear regression analyses were performed with maternal metabolic and inflammatory markers measured postpartum as dependent variables, maternal Hb A 1c Ն5.7% (39 mmol/mol) at delivery as an independent variable, and maternal percentage of body fat as a potential confounder.
A P value Ͻ0.05 was considered statistically significant. All calculations were carried out with the statistical software R3.1.2.
Results
SAMPLE DESCRIPTION
Among 885 women of the PEACHES cohort who had GDM testing, 462 women in whom GDM was ruled out were included in the analysis (Fig. 1) . Table 1 shows the characteristics of the 155 normal-weight and 307 obese women and their children. Mean Hb A 1c concentrations at delivery were significantly higher in obese women. In an obese subgroup (n ϭ 42) ( Table 1) , mean fat proportion at follow-up Ͼ2 years postpartum (median 2.9 years) was 47.4%, and the average postpartum hsCRP concentration was increased [mean (SD) 9.6 (9.6) mg/L] above the reference value (Ͻ5.0 mg/L). First, we aimed to define an upper-range cutoff value for maternal Hb A 1c at delivery. Thus, we analyzed the cumulative distribution of Hb A 1c values at delivery of the cohort of GDM-negative normal-weight women (n ϭ 155) (Fig. 2) . We found that 88% of the healthy normalweight women had an Hb A 1c Ͻ5.7% (39 mmol/mol) at delivery (within reference range). Next, this cutoff value was applied to the cohort of GDM-negative obese women. An approximately 3-fold higher percentage of obese women had Hb A 1c values Ն5.7% (39 mmol/mol) at delivery (Table 1) , although a diagnosis of GDM had been ruled out earlier in pregnancy.
Among the obese GDM-negative women, significant differences were observed regarding total GWG and breastfeeding in those with an Hb A 1c at delivery Ն5.7% vs Ͻ5.7% (39 mmol/mol) (see online Supplemental Table 1).
ASSOCIATIONS OF INCREASED Hb A 1c AT DELIVERY IN OBESE GDM-NEGATIVE MOTHERS WITH OFFSPRING WEIGHT AT BIRTH AND CORD-BLOOD C-PEPTIDE
Children of GDM-negative obese women (n ϭ 307) with Hb A 1c at delivery Ն5.7% vs Ͻ5.7% (39 mmol/ mol) had a higher risk of being born LGA [adjusted odds ratio 3.48 (95% CI, 1.58 -7.90)] and on average a higher birth weight [186 g (95% CI, 80 -293 g)] (Table 2) . Furthermore, mean cord-blood serum C-peptide concentrations were increased by 0.09 ng/mL (95% CI, 0.01-0.17 ng/mL) [0.03 nmol/L (95% CI, 0.00 -0.06 Table 1 . Characteristics of the study population of GDM-negative women: data on main exposure, offspring and maternal outcomes, and potential confounders. Defined by admission to any kind of unit for care exceeding normal newborn care and lasting >24 h. Admission was for any of the following reasons: severe hypoglycemia, hyperbilirubinemia requiring phototherapy, malformation, or respiratory distress. Excluded were data of admissions that were only for sepsis, possible sepsis, or observation. nmol/L)]) in offspring of obese GDM-negative mothers with high Hb A 1c at delivery (Table 2) . High cord-blood serum C-peptide concentrations (Ն90th percentile on the basis of the cumulative distribution of the population of normal-weight GDM-negative women) were associated with a 3.27-fold (95% CI, 1.26 -7.84) increase in the risk of LGA birth weight. When we additionally performed these analyses on the total cohort comprising both obese and normalweight GDM-negative mothers (n ϭ 462), similar results were obtained (see online Supplemental Table 2 ). A separate analysis of the cohort of normal-weight GDMnegative mothers (n ϭ 155) with an Hb A 1c at delivery Ն5.7% vs Ͻ5.7% (39 mmol/mol) revealed a tendency (not statistically significant) toward an increased risk of
LGA births and higher birth weight (see online Supplemental Table 3 ). There was no effect on cord-blood serum C-peptide concentrations.
Regarding clinical neonatal outcomes such as hypoglycemia, severe hypoglycemia, and neonatal care admissions (Table 1) , there were no statistically significant differences in frequencies between obese GDM-negative pregnancies with a maternal Hb A 1c at delivery Ն5.7% vs Ͻ5.7% (39 mmol/mol): hypoglycemia, 11.9% (8/67) vs 6.5% (8/123), P ϭ 0.31; severe hypoglycemia, 4.5% (3/67) vs 4.0% (5/123), P ϭ 1.0; neonatal care admission, 9.4% (9/96) vs 8.7% (17/195) , P ϭ 0.75. Similarly, an insignificant trend for more frequent adverse clinical outcomes in neonates of mothers with Hb A 1c Ն5.7% (39 mmol/mol) at delivery was found for the total cohort of offspring of obese and normal-weight GDM-negative mothers (data not shown).
ASSOCIATIONS OF AN INCREASED Hb A 1c AT DELIVERY IN OBESE GDM-NEGATIVE MOTHERS WITH LONG-TERM MATERNAL POSTPARTUM HEALTH RISKS
There was a clear association of maternal body fat percentage with hsCRP and fibrinogen values measured at the postpartum visit. Therefore, this anthropometric factor was considered a confounder in the analyses of the association of maternal Hb A 1c at delivery with maternal outcome parameters Ͼ2 years after delivery. Other potential confounders such as postpartum smoking status and physical activity were not associated with any postpartum metabolic and inflammatory outcome markers.
At the postpartum visit, obese GDM-negative women with Hb A 1c Ն5.7% (39 mmol/mol) at delivery had a 0.3% (95% CI, 0.1%-0.5%) [3.3 mmol/mol (95% CI, 1.1-5.5 mmol/mol)] higher mean Hb A 1c value (Table 3 ). Those women also had significantly higher mean fasting glucose concentrations by 6.0 mg/dL (95% CI, 2.4 -9.5 mg/dL) [0.33 mmol/L (95% CI, 0.13-0.53 mmol/L)] at the post- , respectively. We also performed these analyses in obese women who had tested positive for GDM (n ϭ 19), yielding similar results for later dysglycemia (see online Supplemental Table 4 ).
Discussion
Maternal obesity in pregnancy and its consequences are an important challenge in health care, since two-thirds of women of childbearing age are overweight or obese in the US today (21 ) . To date, no universal recommendations are available as to the screening and diagnosis of GDM in this high-risk maternal population. The data from our prospective PEACHES mother-child cohort show that about a third of the seemingly nondiabetic obese pregnant women had high Hb A 1c values of Ն5.7% (39 mmol/mol) at the time of delivery. These high values were associated with an increased offspring risk of being born LGA, higher average birth weights, and increased cord-blood serum C-peptide concentrations. They further show associations with adverse long-term effects on biomarkers of glucose metabolism and inflammatory status of obese women several years postpartum. Our findings point to the presence of glycometabolic imbalances in obese pregnancies, despite previous exclusion of GDM even according to stringent criteria, potentially conferring offspring and later maternal risks.
As a biomarker for chronic hyperglycemia, Hb A 1c has an established role in the diagnosis and management of type 2 diabetes. Additionally, Hb A 1c has emerged as a risk marker of cardiovascular disease and a predictor of mortality in nondiabetic adult populations, suggesting that abnormal glycation, even at a subdiabetic level, may already reflect a significant health risk (22 ) . An Hb A 1c cutoff value of Ն5.7% (39 mmol/mol) is now generally considered an indicator of prediabetic conditions and cardiovascular risks in adults (23 ) . In pregnancy, Hb A 1c upper limits were found to be trimester specific and lower than in nonpregnant women (24, 25 ) , although there is no consensus on reference ranges in pregnant women and obese pregnant women in particular (26 ) . Because cutoff values at delivery were lacking, we analyzed a GDMnegative normal-weight population, and results equally showed Hb A 1c Ն5.7% (39 mmol/mol) to be considered abnormal.
The 3.5-fold increased risk of LGA birth weights in obese GDM-negative women of the PEACHES cohort with high Hb A 1c at delivery matches the results of a small study in pregnant women on therapy for GDM, in whom an increased Hb A 1c of Ն5.7% (39 mmol/mol) before delivery was found to be associated with LGA newborns (27 ) . Our findings on LGA status and birth weight were also confirmed in the entire group comprising all GDMnegative mothers (obese and normal weight) and the subgroup of normal-weight GDM-negative mothers, although not all findings reached significance owing to smaller sample sizes. Thus, an increased Hb A 1c value of Ն5.7% (39 mmol/mol) at delivery appears to reflect a state of maternal dysglycemia in pregnancy, with consequences to offspring growth. The increased cord-blood serum C-peptide concentrations in offspring of those women suggests that one mechanism leading to macrosomia was an exaggerated insulin response triggered by maternal hyperglycemia (28 ) . This notion is supported by recent data from nonobese GDM pregnancies showing a strong correlation between maternal Hb A 1c at delivery and glycation of cord-blood hemoglobin, reflecting fetal hyperglycemia exposure (29 ) . Considering that preanalytical and analytical variation may limit the reproducibility of glucose measurements (30 ) , nondiagnostic results of glucose tolerance testing in pregnancy may not always rule out GDM (31 ) . Thus, increases in Hb A 1c at delivery, reflecting mean levels of glycemia over the last weeks of gestation, could also suggest that maternal dysglycemia may have been present even earlier in pregnancy.
Besides GDM, obesity in pregnancy was shown to be independently associated with unfavorable outcomes such as birth weight Ͼ90th percentile and cord-blood serum C-peptide concentrations Ͼ90th percentile in the HAPO data set (32 ) , and the independent associations of obesity and glycemia with adverse outcomes were more than additive. Furthermore, adverse pregnancy outcomes, including macrosomia, in the HAPO study participants were shown to be associated with Hb A 1c earlier in gestation, at the time of glucose tolerance testing, although maternal glucose values of a 75-g OGTT showed stronger associations with offspring outcome (33 (19. 3) mg/dL, P ϭ 0.0007. Thus, these data support the results of the HAPO study referring to continuous relationships between maternal glycemia, even below diagnostic cutoffs, and adverse offspring outcomes, which we find to be associated with high Hb A 1c values at the time of delivery.
To substantiate the potential relevance of high Hb A 1c at delivery for longer-term health risks in obese women, we assessed biomarkers of maternal glucose metabolism and inflammatory status in a subgroup of GDM-negative obese women 2-3 years postpartum. Increases in maternal Hb A 1c of Ն5.7% (39 mmol/mol) at the time of delivery were associated with persistent maternal dysglycemia several years postpartum. We confirmed this association in a separate group of obese women with a diagnosis of GDM, and it appeared to be slightly stronger than that seen in the subgroup of obese GDM-negative women. The association of GDM with the development of postpartum type 2 diabetes and cardiovascular risk factors is well established (34, 35 ) . However, the finding of gestational dysglycemic states associated with increased Hb A 1c at delivery and a risk of later-life health disturbances has not yet been realized as a problem of obese pregnancies.
An important underlying mechanism of obesityrelated health risks, including the development of type 2 diabetes, is through chronic low-grade inflammation induced by responses to excess nutrient supply in metabolic tissues, such as liver and adipose tissue (36 ) . Increased serum concentrations of inflammatory mediators such as hsCRP and fibrinogen, as measured in the obese GDM-negative women at the postpartum visit, reflect this pathological state and were previously shown to be associated with the development of type 2 diabetes (37 ). We found the frequency and extent of "metaflammation" a few years after birth to be higher in those GDM-negative obese women who had increases in Hb A 1c of Ն5.7% (39 mmol/mol) at delivery. This suggests that a high Hb A 1c at delivery might have the potential to serve as a risk indicator. As a consequence, preventive strategies in the early postpartum phase of such obese women, e.g., regular physical activity or phytonutrient-rich diets shown to exert antiinflammatory effects (38 ) , could be considered.
Our findings are based on prospectively collected data of a large contemporary mother-child cohort, thus avoiding recall bias. Another primary strength is the availability of a variety of potential confounding and exposure data, particularly on documented GCTs and OGTTs during pregnancy. Outcome data were ascertained from medical records or measured by trained staff, except for the rates of hypoglycemia and neonatal care admissions. A limitation might be the small sample size of the subgroup of obese women without previous GDM who fulfilled criteria for follow-up investigations 2-3 years after delivery. However, although it could not identify an impact on type 2 diabetes, the sample size was sufficient to detect a difference in postpartum Hb A 1c of 0.3% (95% CI, 0.1%-0.5%) [3.3 mmol/mol (95% CI, 1.1-5.5 mmol/mol)]. Besides indicating glycemic control, Hb A 1c variation may be influenced by nonglycemic factors that lead to states of high or low glycation, such as ethnic disparities, age, and disease conditions including those that affect erythrocyte survival (17 ) . In addition to controlling for such biological variation in this study, analytical and preanalytical variation in Hb A 1c measurements was low.
Considered together, our findings pose questions as to an optimized approach toward monitoring obese pregnancies. Our data should raise clinicians' awareness and confirm that screening and diagnosing GDM is neither designed nor intended to identify all glycometabolic risk conditions. Nevertheless, counseling and lifestyle modifications should be considered for obese pregnant women. Measurement of Hb A 1c at delivery could help to select women who may need closer postpartum health checks. 
